BARDA and JPEO-CBRND form partnership with Smiths Medical to expand domestic manufacturing capacity for safety needles and syringes
BARDA and the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) entered into a Technology Investment Agreement with Smiths Medical, Inc. to expand the capacity to manufacture safety needles and syringes in the United States.
HHS and DoD are working together as part of Operation Warp Speed to ensure the availability of needles and syringes. By taking steps to increase the ability to produce safety needles and syringes in the U.S., the federal government can reduce the nation’s dependence on other countries to provide these potentially lifesaving supplies.
The capacity and infrastructure expansion will allow Smiths Medical to produce additional needles and syringes for use in administering COVID-19 vaccines, as well as supplies for any future pandemics. The U.S. government’s private industry partners will receive priority to purchase these syringes and needles to administer COVID-19 medical countermeasures, such as vaccines.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
About Smiths Medical:
The following information is provided by company and does not indicate endorsement by the federal government of the company or its products.
Smiths Medical is a leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. It is part of Smiths Group, a global leader in applying advanced technologies for markets in threat and contraband detection, energy, medical devices, communications and engineered components. Smiths Group employs around 23,000 people in more than 50 countries.